JBC Avanti Polar Lipids

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schramm, N. L.
Right arrow Articles by Limbird, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schramm, N. L.
Right arrow Articles by Limbird, L. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 274, Issue 35, 24935-24940, August 27, 1999


Stimulation of Mitogen-activated Protein Kinase by G Protein-coupled alpha 2-Adrenergic Receptors Does Not Require Agonist-elicited Endocytosis*

Nicole L. SchrammDagger and Lee E. Limbird§

From the Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6600

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Agonist-elicited receptor sequestration is strikingly different for the alpha 2A- versus alpha 2B-adrenergic receptor (alpha 2-AR) subtypes; the alpha 2B-AR undergoes rapid and extensive disappearance from the HEK 293 cell surface, whereas the alpha 2A-AR does not (Daunt, D. A., Hurt, C., Hein, L., Kallio, J., Feng, F., and Kobilka, B. K. (1997) Mol. Pharmacol. 51, 711-720; Eason, M. G., and Liggett, S. B. (1992) J. Biol. Chem. 267, 25473-25479). Since recent reports suggest that endocytosis is required for some G protein-coupled receptors to stimulate the mitogen-activated protein (MAP) kinase cascade (Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688; Luttrell, L. M., Daaka, Y., Della Rocca, G. J., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 31648-31656; Ignatova, E. G., Belcheva, M. M., Bohn, L. M., Neuman, M. C., and Coscia, C. J. (1999) J. Neurosci. 19, 56-63), we evaluated the differential ability of these two subtypes to activate MAP kinase. We observed no correlation between subtype-dependent agonist-elicited receptor redistribution and receptor activation of the MAP kinase cascade. Furthermore, incubation of cells with K+-depleted medium eliminated alpha 2B-AR internalization but did not eliminate MAP kinase activation, suggesting that receptor internalization is not a general prerequisite for activation of the MAP kinase cascade via Gi-coupled receptors. We also noted that neither dominant negative dynamin (K44A) nor concanavalin A treatment dramatically altered MAP kinase activation or receptor redistribution, indicating that these experimental tools do not universally block G protein-coupled receptor internalization.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The three subtypes of alpha 2-adrenergic receptors (alpha 2-AR)1 signal via the Gi/Go subfamily of G proteins to effect several downstream signaling events (1). Since all three receptor subtypes appear to couple to the same effectors, it is of interest to explore other differences among these subtypes in an effort to understand the functional relevance of subtype diversity. Two alpha 2-AR subtypes manifest differences in agonist-induced receptor redistribution from the cell surface as follows: the alpha 2B-AR becomes rapidly and extensively internalized following agonist occupancy, whereas the alpha 2A-AR does not readily redistribute to an intracellular compartment following agonist occupancy (2, 3). The alpha 2C-AR exists both on the surface and in an intracellular compartment at steady state (2), confounding quantitative assessment of alpha 2C-AR redistribution.

Recent reports suggest that internalization is required for some G protein-coupled receptors (GPCRs) to stimulate the MAP kinase cascade (4-6). The purpose of the current studies was to determine if the differing profiles of agonist-induced internalization of the alpha 2A-AR and alpha 2B-AR subtypes are paralleled by differing rates or extents of MAP kinase activation and whether agents that interfere with agonist-elicited receptor redistribution alter MAP kinase activation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture

HEK 293 cells were maintained in DMEM containing 10% fetal calf serum at 37 °C in a 5% CO2 incubator. Permanent transfectants were generated by LipofectAMINE-mediated co-transfection of the cells with plasmids containing the indicated receptors and a neomycin resistance gene. Cells that survived selection in medium containing 500 µg/ml G418 were screened for expression of the expected receptor by binding of the radiolabeled alpha 2-AR antagonist, [3H]rauwolscine. Clonal cell lines with varying levels of alpha 2-AR expression were kept for further study. The experiments reported here were performed on an alpha 2A-AR expressing cell line that contains 7-8 pmol of receptor per mg of protein and an alpha 2B-AR-expressing cell line that contains 2-4 pmol/mg.

MAP Kinase Stimulation

Permanent transfectants of HEK 293 cells were plated on 60-mm dishes and allowed to multiply until they reached a density of 60-80%. The cells were then serum-deprived overnight. On the day of the experiment, the medium was replaced with fresh serum-free DMEM, DMEM supplemented with 250 µg/ml concanavalin A, or K+-depleted medium as described below to block clathrin-mediated endocytosis. After the pretreatment, the indicated drugs were added directly to the medium on the cells and were swirled to mix. After the indicated times, the cells were washed once with Dulbecco's phosphate-buffered saline containing 1 mM MgCl2 and 0.5 mM CaCl2 (PBS/Ca2+/Mg2+) and then lysed in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8; 2% w/v SDS; 10% glycerol; 50 mM dithiothreitol) supplemented with 1 mM sodium orthovanadate (Sigma), 10 units/ml leupeptin (Sigma), and 10 units/ml aprotinin (Bayer Corp., Kankakee, IL). The lysates were transferred to an Eppendorf tube on ice. When all samples were collected, they were bath sonicated for 30-40 s, then placed in a heating block at 90 °C, allowed to warm to 95 °C, and incubated at 95 °C for 5 min. The lysates were then spun in a microcentrifuge at room temperature for 5 min to remove debris. The supernatants were assayed in Bio-Rad's protein assay for relative protein concentration, and equivalent amounts of protein were loaded on a 10% SDS-polyacrylamide gel for electrophoresis. The gel was run for 160 mA-h and then transferred overnight onto nitrocellulose in transfer buffer (20% methanol; 0.19 M glycine; 25 mM Tris base) at 33 mV.

MAP kinase activation was evaluated using an antibody that recognizes dually phosphorylated (Thr/Tyr) MAP kinase (Promega catalog number V6671) and normalized to total MAP kinase using an antibody that recognizes MAP kinase regardless of its phosphorylation state (New England Biolabs catalog number 9102). To assess activated MAP kinase content, the nitrocellulose blot was incubated in blocking buffer (1× TBS; 0.1% Tween 20; 5% w/v nonfat dry milk) for 1 h at room temperature and then probed with rabbit polyclonal antibody (from Promega) to dually phosphorylated MAP kinase, diluted 1/500 in blocking buffer, for 1 h at room temperature. The blot was washed three times for 5 min each with TBST (2.42 g/liter Tris base; 8.0 g/liter sodium chloride; 0.1% Tween 20; pH 7.6) and then probed with donkey anti-rabbit horseradish peroxidase-linked secondary antibody (1/2000 dilution in blocking buffer) (Amersham Pharmacia Biotech) for 1 h at room temperature. The wash protocol was repeated, and the immunoreactive bands were detected by enhanced chemiluminescence (Amersham Pharmacia Biotech). The blots were then stripped with stripping buffer (62.5 mM Tris-HCl, pH 6.8; 2% SDS; 100 mM 2-mercaptoethanol) for 30 min at 65 °C and reprobed with antibody to total MAP kinase (New England Biolabs) at a 1/500 dilution in blocking buffer overnight at 4 °C, followed by donkey anti-rabbit secondary antibody as described above.

To semi-quantify MAP kinase activation, the enhanced chemiluminescence (ECL) images were scanned into Adobe Photoshop with a UMAX Astra 600 scanner, and the band intensities were measured using NIH Image software. Background pixel density was subtracted from each band's pixel density. The corrected pixel density for active MAP kinase was divided by the corrected pixel density for total MAP kinase to obtain the normalized levels of activated MAP kinase reported in the figures as "active/total."

Cell Surface Receptor Quantitation via Intact Cell ELISA

The introduction of the HA epitope into the amino terminus of alpha 2-ARs expressed in HEK 293 cells provided a tool for quantitation of receptors expressed at the cell surface using a cell surface ELISA, as described previously (2, 7). On day 1, HEK 293 cells stably expressing the receptors of interest were plated on poly-D-lysine-coated 96-well culture plates at a density of 20,000 cells/well. On day 2, the cells were serum-starved overnight. On the morning of day 3, the cells were treated in the absence or presence of agonist as indicated in the figure legends and then washed twice in PBS/Ca2+/Mg2+ to stop the drug treatment and fixed in 4% paraformaldehyde containing 0.12 M sucrose for 20 min at room temperature. The wells were washed three times with PBS/Ca2+/Mg2+ and then incubated for 30 min at 37 °C in DMEM containing 10% sheep serum to block nonspecific antibody binding in subsequent incubations. The 12CA5 antibody directed against the HA epitope was diluted 1/100 in blocking medium and applied for 1 h at 37 °C. The cells were then washed 3 times for 5 min each in PBS/Ca2+/Mg2+ at room temperature. The sheep anti-mouse secondary antibody (Amersham Pharmacia Biotech) was applied at a 1/2500 dilution in blocking medium for 1 h at 37 °C. The wells were then washed three times for 5 min at room temperature in PBS/Ca2+/Mg2+, as above. The colorimetric substrate o-phenylenediamine dihydrochloride (1 mg/ml, Pierce) was added and incubated for 20 min to 1 h at 15 °C. The color development was stopped by the addition of an equal volume of 1 M sulfuric acid. The absorbance at 490 nm in each well was read on a microtiter plate reader. Generally, four replicates of each treatment were performed per experiment.

Reversible Biotinylation Strategy to Quantify Receptor Internalization

Surface receptors were biotinylated on ice with disulfide-cleavable biotin (sulfo-NHS-SS-biotin; Pierce) and treated with a hydrophilic reducing agent, mercaptoethanesulfonic acid (MESNA), after termination of the surface biotinylation reaction. Receptors that are inside the cell at the time of MESNA treatment are protected from reduction and therefore subsequently isolated from the detergent extract by adsorption to streptavidin-agarose. Our protocol was adapted from a previously published procedure (8). For each experiment, HEK 293 clonal cell lines were plated on 60-mm dishes coated with poly-D-lysine and allowed to grow to 70-80% confluence. Cells were serum-starved for 16-18 h prior to each experiment. On the day of the experiment, cells were first treated with serum-free DMEM with or without 250 µg/ml concanavalin A or with K+-depleted medium as described below. Subsequent steps were performed at 4 °C as follows: cells were washed twice with ice-cold phosphate-buffered saline (PBS) containing 1 mM MgCl2 and 0.5 mM CaCl2 or with K+ depletion buffer and then incubated with 100 µg/ml sulfo-NHS-SS-biotin in PBS/Ca2+/Mg2+ or K+ depletion buffer for 30 min at 4 °C. The cells were washed twice with PBS/Ca2+/Mg2+ and once with serum-free DMEM or with K+ depletion buffer at 4 °C. Dishes were then incubated at 37 °C by placement on a rack in a water bath. For agonist activation, the medium was replaced with 37 °C serum-free DMEM or K+ depletion buffer containing 100 µM epinephrine for 5 min at 37 °C (control cells had their medium replaced with warm medium without agonist). The incubation was terminated by replacement of the 37 °C medium with ice-cold DMEM or K+ depletion buffer. The culture dishes were returned to 4 °C, washed twice with ice-cold PBS/Ca2+/Mg2+, and then incubated with 250 mM MESNA in PBS/Ca2+/Mg2+ for two 20-min incubations to release surface-accessible biotinylating reagent via disulfide exchange. The cells were then washed twice with ice-cold serum-free DMEM, and the reducing effect of any residual MESNA was then quenched by incubation with 5 mg/ml iodoacetamide in PBS/Ca2+/Mg2+ for 20 min at 4 °C. Biotinylated receptors resistant to MESNA reversal of biotinylation were defined as "inaccessible." To define total MESNA-accessible receptors on these cell lines, one 60-mm dish per experiment was treated with MESNA immediately following biotinylation at 4 °C to reveal the quantity of surface receptor biotinylation that MESNA can reverse efficiently.

To isolate biotinylated alpha 2-AR, cells were lysed in solubilization buffer (4 mg/ml dodecyl-beta -D-maltoside (Calbiochem), 0.8 mg/ml cholesteryl hemisuccinate (Sigma), 1 mg/ml iodoacetamide (Sigma), 20% glycerol, 25 mM glycyl glycine, 5 mM EDTA, 20 mM HEPES, pH 8.0, 0.1 M NaCl) and homogenized by 5 up/down passages through a 25-gauge needle. Cellular debris was removed by centrifugation in a microcentrifuge at 4 °C for 1 h. The supernatant (defined as the detergent-solubilized extract) was incubated with streptavidin-agarose (80 µl, 1:1 slurry) for 1 h at room temperature. The pass-through was saved, and the beads were washed 3 times with a 1:8 dilution of the solubilization buffer in "binding buffer" (25 mM glycyl glycine; 5 mM EDTA; 20 mM HEPES, pH 8.0; 0.1 M NaCl). Proteins were eluted from streptavidin-agarose in Laemmli buffer containing 15 µg/ml dithiothreitol. The entire eluate was separated by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose, and probed with a 1:1000 dilution in blocking buffer (see above) of HA.11 antibody from Babco to the HA-tagged alpha 2-ARs. Horseradish peroxidase-conjugated sheep anti-mouse secondary antibody (Amersham Pharmacia Biotech) was used at a 1/3000 dilution in blocking buffer. Reactive proteins were visualized by ECL (Amersham Pharmacia Biotech). Bands were quantified by scanning and NIH Image software as described above. To calculate percent internalization, the intensity of the band in the lane where cells were immediately exposed to MESNA (labeled 0', 4 °C) is subtracted as background from all other band intensities, and then the band intensity in the treated lanes ("no epinephrine" or "+epinephrine" after 5 min at 37 °C) is divided by the "total" band intensity, and the result is multiplied by 100.

Treatments for Blocking Receptor Internalization

Potassium Depletion-- The potassium depletion protocol for blocking receptor endocytosis was adapted from previously published methods (9, 10). Clonal cell Lines expressing either alpha 2-AR subtype were incubated at 37 °C for 5 min in hypotonic shock solution (serum-free DMEM and distilled water in a 1:1 ratio). Then they were rinsed once in K+ depletion buffer (100 mM NaCl; 50 mM HEPES, pH 7.4; 1 mM CaCl2; 1 mM MgCl2) and then incubated in the same buffer for 1 h at 37 °C. (Control cells were treated with PBS instead of potassium depletion buffer.) MAP kinase stimulation or biotinylation then proceeded as described above.

Concanavalin A Pretreatment-- Clonal cell lines expressing either alpha 2-AR subtype were incubated with 250 µg/ml concanavalin A (Sigma), made fresh daily in serum-free DMEM, for 30 min at 37 °C, as described previously (11). MAP kinase stimulation or biotinylation then proceeded as described above.

Hypertonic Sucrose Treatment-- Clonal cell lines expressing either alpha 2-AR subtype were washed once and then incubated for 1 h at 37 °C with DMEM containing 0.45 M sucrose, as described previously (9). Drug treatment and analysis then proceeded as described.

Co-expression of K44A Dominant Negative Dynamin-- Parental HEK 293 cells were plated on 6-well plates or 35-mm culture dishes and transiently transfected with cDNAs encoding the HA-tagged alpha 2B-AR and either dominant negative dynamin cDNA (kindly provided by Mark Caron) or "empty" pCMV4 vector as a control. FuGENE 6 transfection reagent (Roche Molecular Biochemicals) was used according to package directions with a FuGENE 6/alpha 2B-AR plasmid/dynamin K44A or control plasmid ratio of 6 µl/1 µg/2 µg. Internalization and MAP kinase activation were assayed as described above. Two wells of a 6-well plate were combined for each data point.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

alpha 2-AR Subtypes Possess Differing Profiles of Agonist-induced Receptor Redistribution-- Two independent experimental strategies were used to examine agonist-elicited receptor redistribution of alpha 2-AR subtypes. An intact cell ELISA performed on HEK 293 cells stably expressing HA-tagged mouse alpha 2A-AR and alpha 2B-AR (see "Experimental Procedures") was used to assess loss of receptor from the cell surface (Fig. 1A). Cell surface ELISAs corroborate earlier morphological findings (2, 3) that the alpha 2A-AR and alpha 2B-AR show differing profiles of agonist-induced internalization. Whereas the alpha 2A-AR demonstrates negligible loss of surface receptors following exposure to maximal agonist concentrations, the alpha 2B-AR subtype demonstrates a 30-40% loss of surface-accessible epitope over the same time.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   The alpha 2B-AR subtype, but not the alpha 2A-AR subtype, rapidly leaves the surface for an inaccessible compartment following agonist occupancy. A, clonal HEK 293 cell lines expressing alpha 2A-AR (closed symbols) or alpha 2B-AR (open symbols) were stimulated with 100 µM epinephrine for the indicated times. Endocytosis was monitored by an intact cell ELISA (see "Experimental Procedures"). The values shown are means ± S.D. for n = 3 or more individual experiments for all time points except for the alpha 2A-AR at 60 min, for which n = 1. B, reversible biotinylation also demonstrates differing profiles of internalization. The 1st lane represents total receptor biotinylated on the cell surface at the end of the incubation with sulfo-NHS-SS-biotin (see "Experimental Procedures"). The 2nd lane demonstrates the effectiveness of MESNA, a membrane-impermeant reducing agent, in reversing the surface biotinylation just after it occurs. Biotinylated cells were then incubated for 5 min at 37 °C without (3rd lane) or with (4th lane) epinephrine as agonist. ECL images are representative of three Western blots. Biotinylated receptors were quantified using NIH image, and the percentage internalized in three separate experiments are shown in the lower panel as the mean ± S.E. Values were compared using two-tailed t tests: *, p = 0.007, #, p = 0.0005.

Receptor internalization also can be examined by quantifying the fraction of surface receptors that moves in a time-dependent fashion to an inaccessible compartment. For these studies, we exploited a reversible biotinylating agent, sulfo-NHS-SS-biotin (Fig. 1B). Biotin remaining on the surface at the end of a particular treatment protocol was removed by treatment with MESNA, a non-permeant reducing agent that cleaves the disulfide bond and liberates the biotinylating reagent from proteins still accessible at the cell surface. MESNA reversal immediately after biotinylation (Fig. 1B; time 0, +) provides an assessment of the amount of biotinylated receptor that is accessible to this reversal reagent at time 0. Further incubation of the cells at 37 °C in the absence or presence of agonist before MESNA reversal of surface biotinylation permits evaluation of agonist-independent versus agonist-accelerated receptor redistribution. As shown in Fig. 1B, the alpha 2A-AR is not extensively redistributed to a MESNA-inaccessible compartment at 37 °C, even in the presence of the agonist epinephrine, whereas the alpha 2B-AR is rapidly internalized (i.e. removed from MESNA accessibility), and this internalization is enhanced by agonist stimulation.

alpha 2A-AR and alpha 2B-AR Subtypes Evoke Similar Profiles of MAP Kinase Stimulation-- Previous studies in heterologous systems have demonstrated alpha 2-AR-elicited activation of MAP kinase (12-16). Recent findings suggest that G protein-coupled receptors may require internalization to activate MAP kinase, particularly via pertussis toxin-sensitive pathways (4, 5). To assess whether receptor internalization is required for MAP kinase activation by alpha 2-ARs, we exploited the differential internalization profiles of the alpha 2A-AR and alpha 2B-AR subtypes and compared their ability to activate MAP kinase in permanent transfectants of HEK 293 cell lines. As shown in Fig. 2, the extent of MAP kinase activation by these two receptor subtypes is similar when measured by the appearance of dually phosphorylated Erk 1 and Erk 2. Stimulation by both subtypes was sensitive to pertussis toxin pretreatment (data not shown), indicating that alpha 2A-AR and alpha 2B-AR are activating MAP kinase via a Gi-coupled pathway, as observed previously (17). We are confident that the stimulation of MAP kinase by epinephrine demonstrated in Fig. 2 is due to activation of the heterologously expressed alpha 2A-AR or alpha 2B-AR in the HEK 293 cells, as activation of MAP kinase is also elicited by the alpha 2-AR agonist UK 14,304 and is blocked by the alpha 2-AR-specific antagonists yohimbine and RX 821002 (data not shown). Furthermore, parental HEK 293 cells did not demonstrate activation by epinephrine prior to introduction of the alpha 2-AR-encoding cDNAs. Unlike the properties of some clonal HEK 293 cell lines reported in the literature (4), we have found no evidence for beta -AR stimulation of MAP kinase in our HEK 293 cells, as MAP kinase is not activated by isoproterenol and the response to epinephrine was not blocked by the beta -AR antagonist, propranolol.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 2.   Similar levels of MAP kinase activation by alpha 2A-AR and alpha 2B-AR subtypes. Clonal HEK 293 cell lines expressing the alpha 2A-AR (A) or alpha 2B-AR (B) were treated for the indicated times with 100 µM epinephrine. MAP kinase activity was assessed by Western blotting for dually phosphorylated MAP kinase and normalized by Western blotting for total MAP kinase. Upper panels, ECL images of Western blots for dually phosphorylated (active) MAP kinase. Images are representative of at least four experiments. Lower panels, normalized levels of activated MAP kinase, expressed as the ratio of active to total MAP kinase enzyme (mean ± S.E. for four experiments). (See "Experimental Procedures.")

Blockade of alpha 2B-AR Internalization Does Not Block MAP Kinase Activation-- The observation that both alpha 2A-AR and alpha 2B-AR subtypes stimulate MAP kinase suggests that receptor internalization, which is highly efficient for the alpha 2B-AR but not for alpha 2A-AR subtype, is not required for MAP kinase activation. Consistent with this interpretation is the realization that maximal MAP kinase activation occurs at 2 min, a time when agonist-elicited receptor loss from the surface, even for alpha 2B-AR, is just beginning (see Fig. 1A).

To assess directly the impact of internalization on MAP kinase activation, we utilized four independent experimental manipulations previously demonstrated to block internalization by clathrin-coated pit pathways as follows: hypertonic sucrose (9), pretreatment with concanavalin A (11), exposure to K+ -depleted medium (9), and co-expression with dominant negative (K44A) dynamin (18, 19). Hypertonic sucrose proved a non-viable strategy in our HEK 293 cell lines, as it caused MAP kinase activation to occur without agonist addition and to a similar extent in parental HEK 293 cells as in permanent transfectants expressing alpha 2-AR subtypes. A second treatment, concanavalin A, is thought to prevent internalization of GPCRs by stabilizing surface integrity due to tetravalent lectin contacts (11). However, concanavalin A was only variably successful in blocking alpha 2B-AR internalization, when assessed via the redistribution of biotinylated alpha 2B-AR into a MESNA-inaccessible compartment (data not shown). This lack of consistent inhibition of alpha 2B-AR internalization may be a consequence of the non-glycosylated nature of the alpha 2B-AR subtype (20). Nevertheless, this finding confounds the use of concanavalin A as a tool for assessing the role of internalization of this subtype in stimulation of MAP kinase.

A third experimental manipulation, co-expression of dominant negative dynamin (K44A), was explored as a tool to block agonist-elicited internalization. However, as assessed in the reversible biotinylation assay, overexpression of dynamin K44A (assessed by Western blotting) did not eliminate alpha 2B-AR internalization, suggesting that these receptors can be internalized via a dynamin-independent pathway (Fig. 3A). Dynamin-independent endocytosis of G protein-coupled receptors has also been noted for dopaminergic and M2 muscarinic receptor subtypes (21, 22). Not surprisingly, co-expression of dynamin K44A with the alpha 2B-AR did not markedly alter MAP kinase activation by the alpha 2B-AR (Fig. 3B).


View larger version (69K):
[in this window]
[in a new window]
 
Fig. 3.   Dynamin K44A does not block endocytosis of alpha 2B-AR or alpha 2B-AR activation of MAP kinase. The alpha 2B-AR was transiently expressed in HEK 293 cells with or without dominant negative dynamin (K44A) as described under "Experimental Procedures." A, receptor redistribution to a MESNA-inaccessible compartment was evaluated as in Fig. 1B (see "Experimental Procedures") and quantified for three independent experiments (mean ± S.E.). In these experiments, internalization was assessed at the 20-min time point, because internalization was undetectable at the 5-min time point in transiently transfected cells. B, MAP kinase activation by epinephrine was evaluated in the absence (upper panel) or presence (middle panel) of dynamin K44A and was quantified for four independent experiments (mean ± S.E.), as shown in the bottom panel.

A fourth experimental manipulation that blocks receptor internalization via clathrin-coated pits, pretreatment in K+-depleted medium, was successful in probing the relationship between receptor internalization and MAP kinase activation. As shown in Fig. 4A, exposure to K+-depleted medium blocks biotinylated surface alpha 2B-AR redistribution into a MESNA-inaccessible compartment, consistent with blockade of alpha 2B-AR internalization. However, as shown in Fig. 4B, alpha 2B-AR readily activates MAP kinase in response to epinephrine under the same conditions. These results demonstrate that internalization is not required for the alpha 2B-AR to stimulate MAP kinase. In fact, the duration of MAP kinase activation appears to be extended upon blockade of alpha 2B-AR internalization by incubation of cells in K+-depleted medium, which is consistent with internalization as a mechanism of desensitization of MAP kinase signaling.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 4.   Blockade of alpha 2B-AR internalization in K+-depleted medium does not block epinephrine stimulation of MAP kinase. HEK 293 cells permanently expressing the alpha 2B-AR were incubated in K+-depleted medium prior to and during stimulation by epinephrine (see "Experimental Procedures"). A, receptor redistribution to a MESNA-inaccessible compartment was measured in control cells (upper panel) or cells exposed to K+-depleted medium (middle panel) following surface biotinylation with the reversible reagent, sulfo-NHS-SS-biotin (see "Experimental Procedures"), as in Fig. 1B. Reversal of biotinylation was performed immediately after biotinylation or after incubation for 5 min at 37 °C with or without the agonist epinephrine. Lower panel, quantification of internalization, mean ± S.E. for three independent experiments (see "Experimental Procedures"). B, MAP kinase activation by epinephrine in the absence (upper panel) or presence (middle panel) of K+-depleted medium. Stimulation was performed for the indicated times, in minutes. Normalized level of activated MAP kinase (active/total) was calculated as described previously and is plotted in the lower panel for the maximal stimulation (2-min time point) and for the point at which desensitization has usually occurred (20-min time point) (mean ± S.E. for three independent experiments).


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The present studies provide two lines of evidence that alpha 2-ARs do not require internalization to evoke MAP kinase activation, in contrast to recent reports implicating internalization as a prerequisite for stimulating the MAP kinase cascade by Gi-mediated GPCR signaling. First, the alpha 2A-AR and alpha 2B-AR subtypes both elicit MAP kinase activation (Fig. 2), despite the greater efficiency of alpha 2B-AR in leaving the surface (Fig. 1A) and appearing in an inaccessible (presumably internal) compartment (Fig. 1B). Second, incubation of HEK 293 cells permanently expressing the alpha 2B-AR subtype in K+-depleted medium eliminates receptor internalization (Fig. 4A) but does not eliminate MAP kinase activation (Fig. 4B).

The reason for the discrepancy between our findings and those previously reported for other G protein-coupled receptors is not certain. The simplest interpretation is that different GPCRs have different mechanistic requirements to stimulate MAP kinase. However, it is also important to note that interpretations from previous studies relied at least in part on transient expression of receptors (4) or on transient expression of dominant negative structures of dynamin or arrestin to block internalization of heterologous or endogenous receptors (4). Our findings suggest that agonist-elicited redistribution of the alpha 2B-AR does not require dynamin-dependent mechanisms (Fig. 3), and thus dynamin K44A does not provide a diagnostic reagent for evaluating the role of endocytosis in alpha 2B-AR-mediated MAP kinase activation. Why different pathways would be utilized by different GPCRs for internalization is not known, although a lack of reliance on dynamin for agonist-elicited endocytosis has also been observed for dopaminergic and muscarinic receptors (21, 22). It may be that, in previous studies examining the impact of dynamin K44A on receptor-mediated MAP kinase activation, expression of mutant dynamin structures may have altered molecular events in addition to those involved in receptor association with clathrin-coated pits (23) or in pinching of clathrin-coated vesicles from the surface (19), and it is these events that play a role in MAP kinase activation by some, but clearly not all, GPCRs.

Our findings provide strong evidence that G protein-coupled receptor internalization is not a general prerequisite for activation of the MAP kinase cascade via Gi-coupled receptors (Fig. 4). Similar results have been obtained previously with chemokine receptors (24). Our results also suggest that MAP kinase activation may be terminated by internalization, since activation of MAP kinase by the alpha 2A-AR persists longer than that by the alpha 2B-AR (Fig. 2), and incubation in K+-depleted medium also parallels sustained activation of the enzyme (Fig. 3B). Future studies will resolve whether different molecular events dictate the duration of receptor-elicited MAP kinase signaling and other Gi-mediated phenomena, such as inhibition of adenylyl cyclase, activation of K+ currents, or suppression of Ca2+ currents.

    ACKNOWLEDGEMENTS

We thank Carol Ann Bonner for the establishment and maintenance of stably transfected HEK 293 cell lines and all members of the Limbird laboratory for helpful scientific discussions.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant HL 25182.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a Harold Stirling Vanderbilt award from Vanderbilt University.

§ To whom correspondence should be addressed: Dept. of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232-6600. Tel.: 615-343-3538; Fax: 615-343-1084; E-mail: Lee.Limbird@mcmail. vanderbilt.edu.

    ABBREVIATIONS

The abbreviations used are: AR, adrenergic receptor; MAP kinase, mitogen-activated protein kinase; ELISA, enzyme-linked immunosorbent assay; MESNA, mercaptoethanesulfonic acid; HEK, human embryonic kidney; GPCR, G protein-coupled receptor; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; HA, hemagglutinin.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Limbird, L. E. (1988) FASEB J. 2, 2686-2695[Abstract]
2. Daunt, D. A., Hurt, C., Hein, L., Kallio, J., Feng, F., and Kobilka, B. K. (1997) Mol. Pharmacol. 51, 711-720[Abstract/Free Full Text]
3. Eason, M. G., and Liggett, S. B. (1992) J. Biol. Chem. 267, 25473-25479[Abstract/Free Full Text]
4. Daaka, Y., Luttrell, L. M., Ahn, S., Della Rocca, G. J., Ferguson, S. S., Caron, M. G., and Lefkowitz, R. J. (1998) J. Biol. Chem. 273, 685-688[Abstract/Free Full Text]
5. Luttrell, L. M., Daaka, Y., Della Rocca, G. J., and Lefkowitz, R. J. (1997) J. Biol. Chem. 272, 31648-31656[Abstract/Free Full Text]
6. Ignatova, E. G., Belcheva, M. M., Bohn, L. M., Neuman, M. C., and Coscia, C. J. (1999) J. Neurosci. 19, 56-63[Abstract/Free Full Text]
7. Schoneberg, T., Liu, J., and Wess, J. (1995) J. Biol. Chem. 270, 18000-18006[Abstract/Free Full Text]
8. Whistler, J. L., and von Zastrow, M. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 9914-9919[Abstract/Free Full Text]
9. Hansen, S. H., Sandvig, K., and van Deurs, B. (1993) J. Cell Biol. 121, 61-72[Abstract/Free Full Text]
10. Sorkin, A., McKinsey, T., Shih, W., Kirchhausen, T., and Carpenter, G. (1995) J. Biol. Chem. 270, 619-625[Abstract/Free Full Text]
11. Toews, M. L., Waldo, G. L., Harden, T. K., and Perkins, J. P. (1984) J. Biol. Chem. 259, 11844-11850[Abstract/Free Full Text]
12. Hawes, B. E., van Biesen, T., Koch, W. J., Luttrell, L. M., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 17148-17153[Abstract/Free Full Text]
13. Williams, N. G., Zhong, H., and Minneman, K. P. (1998) J. Biol. Chem. 273, 24624-24632[Abstract/Free Full Text]
14. van Biesen, T., Luttrell, L. M., Hawes, B. E., and Lefkowitz, R. J. (1996) Endocr. Rev. 17, 698-714[CrossRef][Medline] [Order article via Infotrieve]
15. Flordellis, C. S., Berguerand, M., Gouache, P., Barbu, V., Gavras, H., Handy, D. E., Bereziat, G., and Masliah, J. (1995) J. Biol. Chem. 270, 3491-3494[Abstract/Free Full Text]
16. Bouloumie, A., Planat, V., Devedjian, J. C., Valet, P., Saulnier-Blache, J. S., Record, M., and Lafontan, M. (1994) J. Biol. Chem. 269, 30254-30259[Abstract/Free Full Text]
17. Alblas, J., van Corven, E. J., Hordijk, P. L., Milligan, G., and Moolenaar, W. H. (1993) J. Biol. Chem. 268, 22235-22238[Abstract/Free Full Text]
18. Damke, H. B., Takeshi, Warnock, Dale, E., Schmid, and Sandra, L. (1994) J. Cell Biol. 127, 915-934[Abstract/Free Full Text]
19. Herskovits, J. S., Burgess, C. C., Obar, R. A., and Vallee, R. B. (1993) J. Cell Biol. 122, 565-578[Abstract/Free Full Text]
20. Wilson, A. L., Seibert, K., Brandon, S., Cragoe, E. J., Jr., and Limbird, L. E. (1991) Mol. Pharmacol. 39, 481-486[Abstract]
21. Vickery, R. G., and von Zastrow, M. (1999) J. Cell Biol. 144, 31-43[Abstract/Free Full Text]
22. Vogler, O., Bogatkewitsch, G. S., Wriske, C., Krummenerl, P., Jakobs, K. H., and van Koppen, C. J. (1998) J. Biol. Chem. 273, 12155-12160[Abstract/Free Full Text]
23. Zhang, J., Barak, L. S., Winkler, K. E., Caron, M. G., and Ferguson, S. S. (1997) J. Biol. Chem. 272, 27005-27014[Abstract/Free Full Text]
24. Neptune, E. R., and Bourne, H. R. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 14489-14494[Abstract/Free Full Text]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
ReproductionHome page
S. Cikos, P. Rehak, S. Czikkova, J. Vesela, and J. Koppel
Expression of adrenergic receptors in mouse preimplantation embryos and ovulated oocytes
Reproduction, June 1, 2007; 133(6): 1139 - 1147.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
W. B. Sneddon, Y. Yang, J. Ba, L. M. Harinstein, and P. A. Friedman
Extracellular signal-regulated kinase activation by parathyroid hormone in distal tubule cells
Am J Physiol Renal Physiol, March 1, 2007; 292(3): F1028 - F1034.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Q. Wang, R. Lu, J. Zhao, and L. E. Limbird
Arrestin Serves as a Molecular Switch, Linking Endogenous {alpha}2-Adrenergic Receptor to SRC-dependent, but Not SRC-independent, ERK Activation
J. Biol. Chem., September 8, 2006; 281(36): 25948 - 25955.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
A. E. Brady, Q. Wang, P. B. Allen, M. Rizzo, P. Greengard, and L. E. Limbird
{alpha}2-Adrenergic Agonist Enrichment of Spinophilin at the Cell Surface Involves {beta}{gamma} Subunits of Gi Proteins and Is Preferentially Induced by the {alpha}2A-Subtype
Mol. Pharmacol., May 1, 2005; 67(5): 1690 - 1696.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. J. Samuvel, L. D. Jayanthi, N. R. Bhat, and S. Ramamoorthy
A Role for p38 Mitogen-Activated Protein Kinase in the Regulation of the Serotonin Transporter: Evidence for Distinct Cellular Mechanisms Involved in Transporter Surface Expression
J. Neurosci., January 5, 2005; 25(1): 29 - 41.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
Q. Wang, J. Zhao, A. E. Brady, J. Feng, P. B. Allen, R. J. Lefkowitz, P. Greengard, and L. E. Limbird
Spinophilin Blocks Arrestin Actions in Vitro and in Vivo at G Protein-Coupled Receptors
Science, June 25, 2004; 304(5679): 1940 - 1944.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Huang, Y. Sun, and X.-Y. Huang
Distinct Roles for Src Tyrosine Kinase in {beta}2-Adrenergic Receptor Signaling to MAPK and in Receptor Internalization
J. Biol. Chem., May 14, 2004; 279(20): 21637 - 21642.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. D. Jayanthi, D. J. Samuvel, and S. Ramamoorthy
Regulated Internalization and Phosphorylation of the Native Norepinephrine Transporter in Response to Phorbol Esters: EVIDENCE FOR LOCALIZATION IN LIPID RAFTS AND LIPID RAFT-MEDIATED INTERNALIZATION
J. Biol. Chem., April 30, 2004; 279(18): 19315 - 19326.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. M. Holstein, K. A. Berg, L. M. F. Leeb-Lundberg, M. S. Olson, and C. Saunders
Calcium-sensing Receptor-mediated ERK1/2 Activation Requires G{alpha}i2 Coupling and Dynamin-independent Receptor Internalization
J. Biol. Chem., March 12, 2004; 279(11): 10060 - 10069.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
S. J. Kim, M. Y. Kim, E. J. Lee, Y. S. Ahn, and J.-H. Baik
Distinct Regulation of Internalization and Mitogen-Activated Protein Kinase Activation by Two Isoforms of the Dopamine D2 Receptor
Mol. Endocrinol., March 1, 2004; 18(3): 640 - 652.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
W. Wang, H. H. Loh, and P.-Y. Law
The Intracellular Trafficking of Opioid Receptors Directed by Carboxyl Tail and a Di-leucine Motif in Neuro2A Cells
J. Biol. Chem., September 19, 2003; 278(38): 36848 - 36858.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. E. Brady, Q. Wang, R. J. Colbran, P. B. Allen, P. Greengard, and L. E. Limbird
Spinophilin Stabilizes Cell Surface Expression of {alpha}2B-Adrenergic Receptors
J. Biol. Chem., August 22, 2003; 278(34): 32405 - 32412.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Pan, E. V. Gurevich, and V. V. Gurevich
The Nature of the Arrestin{middle dot}Receptor Complex Determines the Ultimate Fate of the Internalized Receptor
J. Biol. Chem., March 21, 2003; 278(13): 11623 - 11632.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. Roland, B. J. Murphy, B. Ahr, V. Robert-Hebmann, V. Delauzun, K. E. Nye, C. Devaux, and M. Biard-Piechaczyk
Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling
Blood, January 15, 2003; 101(2): 399 - 406.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
K. E. Weatherby, B. S. Zwilling, and W. P. Lafuse
Resistance of Macrophages to Mycobacterium avium Is Induced by {alpha}2-Adrenergic Stimulation
Infect. Immun., January 1, 2003; 71(1): 22 - 29.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. L. Berkeley and A. I. Levey
Cell-Specific Extracellular Signal-Regulated Kinase Activation by Multiple G Protein-Coupled Receptor Families in Hippocampus
Mol. Pharmacol., January 1, 2003; 63(1): 128 - 135.
[Abstract] [Full Text] [PDF]


Home page
Mol Biol EvolHome page
O. Madsen, D. Willemsen, B. M. Ursing, U. Arnason, and W. W. de Jong
Molecular Evolution of the Mammalian Alpha 2B Adrenergic Receptor
Mol. Biol. Evol., December 1, 2002; 19(12): 2150 - 2160.
[Abstract] [Full Text] [PDF]